New cancer treatments, especially those targeting specific genetic mutations or utilizing immunotherapy, have shown promising results in improving patient outcomes. While the initial costs of these treatments may be high, the long-term benefits such as prolonged survival and decreased need for hospital visits can lead to substantial cost savings. Moreover, successful treatments can be patented, leading to financial returns through licensing and sales.
